What is Orladeyo (berotralstat) and its Crystalline Salt Form?
Orladeyo (berotralstat) is a medication used to prevent attacks in adults and adolescents with hereditary angioedema (HAE). The drug's synthesis involves a specific crystalline salt form of berotralistat. This form is a berotralistat dihydrochloride anhydrous crystalline salt [1]. The use of a specific crystalline form can impact a drug's stability, solubility, and manufacturing processes [2].
When Does the Patent for Berotralistat Expire?
The patent situation for berotralistat is complex and involves multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes. As of late 2023, DrugPatentWatch.com data indicates that patents covering berotralistat's composition of matter and formulation are set to expire in the mid-2030s. However, this does not preclude earlier market entry for generic versions if other patents, such as those related to manufacturing or specific salt forms, expire sooner or are successfully challenged [3].
What is the Significance of Berotralistat's Crystalline Salt Form in Patent Law?
The specific crystalline salt form of a drug, such as the dihydrochloride anhydrous crystalline salt of berotralistat, can be independently patented. These "polymorph patents" protect a particular solid-state form of the active pharmaceutical ingredient. Pharmaceutical companies often seek these patents to extend market exclusivity beyond the expiry of the primary composition of matter patent. Challenges to these patents can occur if a generic manufacturer can demonstrate that their proposed product does not infringe the patent or if the patent is deemed invalid [2, 3].
Can Generic Versions of Berotralistat Enter the Market Before Patent Expiry?
The market entry of generic versions of berotralistat before the expiration of all related patents depends on several factors. Generic manufacturers may attempt to launch their products by challenging existing patents, arguing they are invalid or not infringed. Additionally, if there are patents that expire earlier than the main composition of matter patent, or if the crystalline salt form patent is overcome, it could open a pathway for generic competition [3].
What are the Potential Risks Associated with Berotralistat Use?
While specific patient concerns are not detailed in the provided information, as with any medication, potential risks are associated with the use of berotralistat. These can include side effects, drug interactions, and the possibility of therapeutic failure. Patients should discuss any concerns with their healthcare providers [1].
How Does Berotralistat Work to Prevent HAE Attacks?
Berotralistat is a plasma kallikrein inhibitor. By inhibiting plasma kallikrein, it reduces the production of bradykinin, a molecule that plays a key role in the swelling attacks characteristic of HAE [1].
Who is Developing and Manufacturing Berotralistat?
BioCryst Pharmaceuticals developed and manufactures berotralistat [1].
What are the Alternatives to Berotralistat for HAE Treatment?
Other treatment options for HAE exist, including prophylactic therapies and on-demand treatments that target different pathways or mechanisms involved in HAE attacks. These alternatives may include other kallikrein inhibitors, C1 esterase inhibitors, or therapies that address bradykinin receptors [1].
---
Sources:
[1] Orladeyo (berotralstat) Prescribing Information, BioCryst Pharmaceuticals. (Accessible via official drug information databases and manufacturer websites.)
[2] Crystalline forms and polymorphs in drug development. (General information on pharmaceutical salt forms and patents, often discussed in scientific literature and patent law resources.)
[3] Berotralistat Patent Expiration and Generic Entry Analysis. DrugPatentWatch.com. (Information from DrugPatentWatch.com regarding patent timelines and potential generic competition for berotralistat.)